BTIG analyst Julian Harrison raised the firm’s price target on CymaBay to $22 from $18 and keeps a Buy rating on the shares after its Q2 results. The large total addressable market corresponding to IDEAL – a study to evaluate seladelpar’s effects on biochemical normalization in PBC patients – has a good chance of materializing into a real opportunity for seladelpar, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- Guggenheim starts CymaBay at Buy, sees PBC market leadership potential
- CymaBay initiated with a Buy at Guggenheim
- CymaBay reports Q2 EPS (1c), consensus (20c)
- CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update
- CymaBay initiates Phase 3 study of Seladelpar